SAFETY, TOLERABILITY, AND BIOLOGICAL ACTIVITY OF AXA1125 AND AXA1957 IN A PROSPECTIVE 16-WEEK RANDOMIZED, PLACEBO-CONTROLLED STUDY IN SUBJECTS WITH NAFLD WITH AND WITHOUT TYPE 2 DIABETES

被引：0
|
作者：
Harrison, Stephen A. [1 ]
Gunn, Nadege T. [2 ]
Baum, Seth J. [3 ]
Younes, Ziad H. [4 ]
Kohli, Anita [5 ]
Patil, Rashmee [6 ]
Koziel, Margaret J. [7 ]
Chera, Harinder [7 ]
Zhao, Jeff [7 ]
Chakravarthy, Manu V. [7 ]
机构：
[1] Pinnacle Clin Res Ctr, San Antonio, TX USA
[2] Pinnacle Clin Res, San Antonio, TX USA
[3] Excel Med Clin Trials, Boca Raton, FL USA
[4] Gastro One, Germantown, TN USA
[5] Arizona Liver Hlth, Chandler, AZ USA
[6] South Texas Res Inst, Edinburg, TX USA
[7] Axcella Hlth Inc, Cambridge, MA USA
来源：
HEPATOLOGY | 2020年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1694
引用
收藏
页码：1032 / 1033
页数：2
相关论文
共 44 条
  • [1] BIOLOGICAL ACTIVITY OF AXA1125 AND AXA1957 ON GLUCOSE, INSULIN, HOMA-IR, AND HbA1c AND MEASURES OF LIVER FAT AND FIBROINFLAMMATION IN A PROSPECTIVE 16-WEEK RANDOMIZED, PLACEBO-CONTROLLED STUDY IN SUBJECTS WITH NAFLD AND TYPE 2 DIABETES
    Baum, Seth J.
    Harrison, Stephen A.
    Gunn, Nadege T.
    Younes, Ziad H.
    Kohli, Anita
    Patil, Rashmee
    Chera, Harinder
    Zhao, Jeff
    Chakravarthy, Manu V.
    Kozier, Margaret J.
    HEPATOLOGY, 2020, 72 : 1012 - 1012
  • [2] Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease
    Harrison, Stephen A.
    Baum, Seth J.
    Gunn, Nadege T.
    Younes, Ziad H.
    Kohli, Anita
    Patil, Rashmee
    Koziel, Margaret J.
    Chera, Harinder
    Zhao, Jeff
    Chakravarthy, Manu V.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 (12): : 2399 - 2409
  • [3] Multifactorial effects of AXA1125 and AXA1957 observed on markers of metabolism, inflammation and fibrosis: a 16-week randomized placebo-controlled study in subjects with non-alcoholic fatty liver disease (NAFLD) with and without type 2 diabetes (T2D)
    Harrison, Stephen A.
    Baum, Seth J.
    Gunn, Nadege T.
    Younes, Ziad H.
    Kohli, Anita
    Patil, Rashmee
    Koziel, Margaret J.
    Chera, Harinder
    Zhao, Jeff
    Chakravarthy, Manu V.
    JOURNAL OF HEPATOLOGY, 2020, 73 : S123 - S123
  • [4] Efficacy and Tolerability of AXA1125, an Endogenous Metabolic Modulator Composition, in Fatigue-predominant Long COVID: A Randomized, Double-blind, Placebo-controlled Study
    Finnigan, L.
    Cassar, M.
    Koziel, M.
    Azer, K.
    Kirby, D.
    Pradines, J.
    Montgomery, H.
    Neubauer, S.
    Valkovic, L.
    Raman, B.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [5] Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study
    Del Prato, Stefano
    Kang, Jahoon
    Trautmann, Michael E.
    Stewart, John
    Sorli, Christopher H.
    Derwahl, Michael
    Soto, Alfonso
    Yoon, Kun-Ho
    DIABETES OBESITY & METABOLISM, 2020, 22 (07): : 1176 - 1186
  • [6] Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trial
    Ross, S.
    Thamer, C.
    Cescutti, J.
    Meinicke, T.
    Woerle, H. J.
    Broedl, U. C.
    DIABETES OBESITY & METABOLISM, 2015, 17 (07): : 699 - 702
  • [7] A PHASE 2, 16-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY AND EFFICACY OF REPEATED DOSES OF KB001-A IN SUBJECTS INFECTED WITH P. AERUGINOSA
    Chmiel, J.
    Hamblett, N. M.
    Geller, D.
    Konstan, M.
    VanDevanter, D.
    Thompson, V
    Molfino, N.
    Yarranton, G.
    Shreeniwas, R.
    PEDIATRIC PULMONOLOGY, 2015, 50 : 272 - 272
  • [8] Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial
    Schumm-Draeger, P. -M.
    Burgess, L.
    Koranyi, L.
    Hruba, V.
    Hamer-Maansson, J. E.
    de Bruin, T. W. A.
    DIABETES OBESITY & METABOLISM, 2015, 17 (01): : 42 - 51
  • [9] Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease -: A 16-week randomized, double-blind, placebo-controlled study
    Lautamäki, R
    Airaksinen, KEJ
    Seppänen, M
    Toikka, J
    Luotolahti, M
    Ball, E
    Borra, R
    Härkönen, R
    Iozzo, P
    Stewart, M
    Knuuti, J
    Nuutila, P
    DIABETES, 2005, 54 (09) : 2787 - 2794
  • [10] Allogeneic Mesenchymal Precursor Cells in Type 2 Diabetes: A Randomized, Placebo-Controlled, Dose-Escalation Safety and Tolerability Pilot Study
    Skyler, Jay S.
    Fonseca, Vivian A.
    Segal, Karen R.
    Rosenstock, Julio
    DIABETES CARE, 2015, 38 (09) : 1742 - 1749
12345